Drug Patents owned by Acadia Pharms Inc

1. Drug name - NUPLAZID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7923564 ACADIA PHARMS INC Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms
Sep, 2025

(2 years from now)

US7732615 ACADIA PHARMS INC N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
Jun, 2028

(5 years from now)

US7601740 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Apr, 2030

(7 years from now)

CN101500568A ACADIA PHARMS INC Pharmaceutical Formulations Of Pimavanserin
Jul, 2011

(11 years ago)

CN102028949A ACADIA PHARMS INC Selective Serotonin 2A/2C Receptor Inverse Agonists As Therapeutics For Neurodegenerative Disease
Jul, 2013

(9 years ago)

CN101778821A ACADIA PHARMS INC N-(4-Fluorobenzyl)-N-(1-Piperidine--4-Yl)-N '-(4-(2) Phenyl Methyl) Urine And Tartrate And Compound And Crystal Form
Aug, 2013

(9 years ago)

CN1816524A ACADIA PHARMS INC A Selective Serotonin 2A/2C Receptor Inverse Agonists For The Treatment Of Neurodegenerative Diseases
Jan, 2024

(1 year, 3 months from now)

CN101780080A ACADIA PHARMS INC Selective Serotonin 2A/2C Receptor Inverse Agonist For Treating Neurodegenerative Disease
Jan, 2024

(1 year, 3 months from now)

CN1816524B ACADIA PHARMS INC Selective Serotonin 2A/2C Receptor Inverse-Agonist For Treating Neurodegenerative Disease
Jan, 2024

(1 year, 3 months from now)

CN101780080B ACADIA PHARMS INC Selective Serotonin 2A/2C Receptor Inverse-Agonist For Treating Neurodegenerative Disease
Jan, 2024

(1 year, 3 months from now)

CN101031548A ACADIA PHARMS INC Salt Of N-(4-Fluorobenzyl)-N-(1-Methyl Piperidine-4-Yl)-N'-(4-(2-Methyl Propyloxy)-Phenyl Methyl) Carbamide And Its Preparation
Sep, 2025

(2 years from now)

CN101035759B ACADIA PHARMS INC N - (4) -N-(1 -4) -N '-(4 - (2) Phenylmethyl) Urine And Synthesis And Crystalline Form Of Tartrate
Sep, 2025

(2 years from now)

CN102153505A ACADIA PHARMS INC N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-Yl)-N'-(4-(2-Methylpropyloxy)Phenylmethyl) Carbamide, Synthetization Of Tartrate And Crystalline Form
Sep, 2025

(2 years from now)

CN101035759A ACADIA PHARMS INC N-(4-Fluorobenzyl)-N-(1-Methyl Piperidine-4-Radical)-N'-(Methyl Propoxy) Phenyl Methyl) Carbamide, Synthesis And Crystalline Form Of Its Tartrate
Sep, 2025

(2 years from now)

CN102153505B ACADIA PHARMS INC N - (4) -N-(1 -4) -N '-(4 - (2) Phenylmethyl) Carbamide And Its Synthesis And Crystalline Form Of The Tartrate
Sep, 2025

(2 years from now)

CN101031548B ACADIA PHARMS INC Salts Of N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-Yl)-N'-(4-(2-Methylpropyloxy) Phenylmethyl) Carbamide And Their Preparation
Sep, 2025

(2 years from now)

IN235410B ACADIA PHARMS INC A Composition Comprising Selective Serototonin 2A/2C Receptor Inverse Agnoist
Jan, 2024

(1 year, 3 months from now)

IN200501635P2 ACADIA PHARMS INC A Composition Comprising Selective Serototonin 2A/2C Receptor Inverse Agnoist
Jan, 2024

(1 year, 3 months from now)

IN200701144P2 ACADIA PHARMS INC Synthesis Of N-(Fluorobenzyl)-N-(Methylpiperidin-4-Yl)-N'-(4-(2 Methylpropyloxy) Phenylmethyl) Carbamide And Its Tartrate Salt And Crystalline Forms
Sep, 2025

(2 years from now)

IN265372B ACADIA PHARMS INC Synthesis Of N- (Fluorobenzyl)-N- (Methylpiperidin-4- Yl)-N'-(4-(2 Methylpropyloxy) Phenylmethyl) Carbamide And Its Tartrate Salt And Crystalline Forms
Sep, 2025

(2 years from now)

EP1587789B1 ACADIA PHARMS INC Selective Serotonin 2A/2C Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseases
Jan, 2024

(1 year, 3 months from now)

EP1587789A2 ACADIA PHARMS INC Selective Serotonin 2A/2C Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseases
Jan, 2024

(1 year, 3 months from now)

EP2009000B1 ACADIA PHARMS INC Selective Serotonin 2A/2C Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseases
Jan, 2024

(1 year, 3 months from now)

EP2009000A1 ACADIA PHARMS INC Selective Serotonin 2A/2C Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseases
Jan, 2024

(1 year, 3 months from now)

EP1794126B1 ACADIA PHARMS INC Crystalline Form Of N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-Yl)-N'-(4-(2-Methylpropyloxy)Phenylmethyl)Carbamide Hemi-Tartrate
Sep, 2025

(2 years from now)

EP2289879A1 ACADIA PHARMS INC Synthesis Of A Crystalline Form Of N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-Yl)-N'-(4-(2-Methylpropyloxy)Phenylmethyl)Carbamide Tartrate Salt
Sep, 2025

(2 years from now)

EP1794126A1 ACADIA PHARMS INC Crystalline Form Of N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-Yl)-N'-(4-(2-Methylpropyloxy)Phenylmethyl)Carbamide Hemi-Tartrate
Sep, 2025

(2 years from now)

EP2289879B1 ACADIA PHARMS INC Synthesis Of A Crystalline Form Of N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-Yl)-N'-(4-(2-Methylpropyloxy)Phenylmethyl)Carbamide Tartrate Salt
Sep, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028944 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Jan, 2024

(1 year, 3 months from now)

US8921393 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Jan, 2024

(1 year, 3 months from now)

US8618130 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Jan, 2024

(1 year, 3 months from now)

US9566271 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Jan, 2024

(1 year, 3 months from now)

US7659285 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Aug, 2026

(3 years from now)

US10953000 ACADIA PHARMS INC Combination of pimavanserin and cytochrome P450 modulators Mar, 2037

(14 years from now)

US10517860 ACADIA PHARMS INC Combination of pimavanserin and cytochrome P450 modulators Mar, 2037

(14 years from now)

US10849891 ACADIA PHARMS INC Formulations of pimavanserin Aug, 2038

(15 years from now)

US10646480 ACADIA PHARMS INC Formulations of pimavanserin Aug, 2038

(15 years from now)

US10449185 ACADIA PHARMS INC Formulations of pimavanserin Aug, 2038

(15 years from now)

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis; Treatment of a neurodegenerative disease or a symptom thereof; Treatment of psychosis or a symptom thereof; Treatment of parkinson's disease psychosis

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE TABLET;ORAL Prescription
EQ 17MG BASE TABLET;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.